Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 295

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Developing aptamers into therapeutics

Open access
White, Rebekah R., Sullenger, Bruce A., Rusconi, Christopher P.·2000·Journal of Clinical Investigation

Abstract

Nucleic acid therapeuticsThe idea of using nucleic acid molecules as therapeutic agents was conceived in the 1970s with the development of antisense strategies.Antisense compounds are single-stranded nucleic acids that, in principle, disrupt the synthesis of a targeted protein by hybridizing in a sequence-dependent manner to the mRNAs that encode it.The mechanism of inhibition by nucleic acid aptamers is fundamentally different.Aptamers are single-stranded nucleic acids that directly inhibit a protein's function by folding into a specific three-dimensional structure that dictates high-affinity binding to the targeted protein.Through iterative in vitro selection techniques, aptamers can be generated that bind essentially any protein (or small molecule) target.A high-affinity, specific inhibitor can theoretically be made to order, provided that a small quantity of pure target is available.Because they inhibit the activity of existing proteins directly, aptamers are more similar to monoclonal antibody or small molecule drugs than to antisense compounds, and this property greatly increases the number of clinical indications that are potentially treatable by nucleic acid-based compounds.Aptamers have been generated against a wide variety of targets, a complete discussion of which is beyond the scope of this article (for review, see ref. 1).As with any molecular therapeutic approach, the inhibitor is only as effective as the target is important.Through their ability to specifically inhibit a molecule of interest, aptamers have already proven useful as reagents for target validation in a variety of disease models.The next step, therapeutic utility, will depend on the efficacy of these novel compounds in humans.In this Perspective, we will focus on the development and status of aptamers as therapeutic molecules. Nucleic acids as direct antagonists of protein functionMany viruses, including HIV, have evolved small, structured RNA sequences to recruit viral and host cell proteins to perform essential functions in viral replication.The HIV virus, for example, employs the TAR and RRE RNA sequences to recruit the essential viral regulatory proteins tat and rev, which aid in Developing aptamers into therapeutics

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci11325

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 295

Metadata

Authors
White, R. R., Sullenger, B. A., & Rusconi, C. P.
Venue
Journal of Clinical Investigation
Published
2000-10-15
Volume
106
Issue
8
Pages
929-934
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2077130806
Cited by
295
References
31
FWCI
2.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Developing aptamers into therapeutics. https://app.cochat.ai/papers/10.1172/jci11325
The paper
White, R. R., Sullenger, B. A., & Rusconi, C. P. (2000). Developing aptamers into therapeutics. Journal of Clinical Investigation. https://doi.org/10.1172/jci11325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.